USO 25009
LYL314-101: A PHASE 1/2 MULTI-CENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF LYL314, A CD19/CD20 DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IN PARTICIPANTS WITH AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
Disease Types: CAR-T
Eligibility Requirements:
• Subjects must have histologically confirmed aggressive B-cell NHL
including DLBCL, PBMCL, FL3B, DLBCL arising from follicular
lymphoma, and HGBL
• Subjects must have received 2 prior LOT
• Must have received an anthracycline & an anti-CD20 mAb
and be CAR T naïve
• Subjects with tFL must receive at least 1 LOT after
transformation to DLBCL
• Subjects must have disease progression after last regimen or
failure to achieve CR to last LOT
• Subjects with active CNS involvement are excluded
• Subjects with history of allogeneic stem cell or solid organ
transplant.
For more information on this trial CLICK HERE .
Available at: